Background: There is limited information on a special subtype of Acute myeloid leukemia (AML) characterized by >20% myeloblasts and >20% abnormal promyelocytes in bone marrow and peripheral blood. Objective: The objective of the present investigation was to explore the clinical and laboratory features of seven patients with AML-M2/M3.
Background
Acute myeloid leukemia (AML) is characterized by clonal expansion of myeloid blasts in bone marrow (BM), peripheral blood (PB), or other tissues. In the World Health Organization (WHO) scheme (2008), a myeloid neoplasm with 20% or more myeloblasts in the PB or BM is considered to be AML. Acute myeloid leukemia with the gene rearrangement t (8; 21) (q22; q22); (AML1/ETO), which is also referred to as the RUNX1 gene, and AML with the rearrangement t (15; 17) (q22; q12) (PML/RARα) are considered distinct AML subtypes. In the FrenchAmerican-British (FAB) classification scheme for AML, the criteria for AML-M2 is 30% to 89% myeloblasts, >10% promyelocytes and neutrophilic myelocyte, and <20% monocytes [1] [2] [3] [4] [5] [6] [7] [8] [9] .
Two cases of AML with simultaneous PML/RARa and AML1/ETO gene rearrangement have been reported [10] . We have encountered seven cases with myeloblast fractions ranging from 36 − 85% and a fraction of abnormal promyelocytes from 24 − 49.5%, with one patient presenting with simultaneous AML1/ETO and PML/RARα fusion genes [11] [12] [13] [14] [15] [16] [17] [18] . In this paper, we retrospectively analyze all seven cases diagnosed as AML-M2/M3, to present a general picture of the clinical symptoms, laboratory results, prognosis, and treatment responses of this unusual AML subtype.
Materials and methods

Clinical information
The current study was approved by the Department of Hematology of the First Affiliated Hospital of Guangzhou Medical University. Patients were enrolled and treated from Jan. 2008 to Jun. 2012. Study eligibility criteria included availability of bone marrow histology and cytogenetic information at the time of referral to the Department of Hematology. Acute myeloid leukemia was diagnosed according to the World Health Organization criteria [1, 2, 8] . During the study period, seven patients, aged 8 to 76, were newly diagnosed with AML-M2/M3 based on >30% myeloblasts and >20% abnormal promyelocytes as well as predominant myeloperoxidase (MPO or POX) and naphthol AS-D chloroacetate esterase (AS-DCE, or specific esterase, SE) positive status. Bone marrow smears, PB smears, and detailed morphological, immunochemical, and cytogenetic analyses of BM biopsy tissue were conducted for each patient. The myeloid lineage was assessed using antibodies against CD9, CD11b, CD13, CD15, CD33, CD34, CD38, CD45, CD56, CD64, CD117, HLA-DR, and cMPO. The lymphocyte T cell lineage was assessed using antibodies against CD2, CD3, CD5 and CD7, while the B cell lineage was assessed using antibodies against CD19, CD20, CD22, and CD79a.
Flow cytometry
The flow cytometer of COULTER EPICS XL type with 488 nm excitation light source was used in the present investigation, and System II software was employed for analysis. After calibration with Fluorescent Microspheres and adjustment Fluorescence compensation of the machine, three-color fluorescent staining of the same type sample was done to serve as negative control to exclude nonspecific fluorescence staining. According to the degree of expression of CD45 and particle size of SSC, the cells were divided into granulocytes, monocytes, lymphocytes, immature lymphocyte populations and immature myeloid cells group, red blood cells and debris cells. After analysis of each cell group, naive cells were determined. The expression of antigen was analyzed by two-dimensional phenotypic spectrum. by flow cytometry, and results of cytogenetic analysis for all seven case patients are summarized in Tables 1,  2 , 3, and 4. The majority of cells were positive for antigens of the myeloid lineage and negative for antigens of the lymphocytic lineage.
Case studies
Chemotherapy
Five of the six cases were treated by standard chemotherapy [17, 18] (daunorubicin + cytarabine, DA) combined with all-trans retinoic acid (ATRA) or arsenic trioxide (ATO). The other case (case 6) was first treated with ATRA, compound realgar, and natural indigo tablets (CRINT), and then given reduced dose DA [19] . After the initial treatment, 5 cases achieved complete remission (CR), including one case with recurrence after three months that transformed into AML-M2 (Case 6). The average time to achieve CR was 37 days. Two cases did not achieved remission (including one death). After stem cell transplantation, patients with AML-M2/M3 might have prolonged event-free survival (Table 5) .
Results
When newly diagnosis, 85.7% of case patients (6/7) had fever, 71.4% (5/7) had sternum pressing pain, hemorrhagic symptoms, and anemia, 28.6% (2/7) presented with hepatomegaly or splenomegaly, 100% had leukocytosis or leukopenia, and thrombocytopenia, 28.6% showed reduced hemocytes (all lineages), 100% had coagulation abnormalities, and 85.7% had elevated serum LDH. All patients had >20% myeloblasts and >20% abnormal promyelocytes, of which 71.4% had >30% BM myeloblasts and abnormal promyelocytes. All six patients tested were MPO (+). Six patients were PML/ RARа positive and two of these patients harbored both the AML1/ETO and PML/RARа fusion genes. Immunophenotyping (Table 3) showed that BM and PB cells expressed antigens of the myeloid lineage, including CD9, CD11b, CD13, CD15, CD33, CD34, CD38, CD45, CD56, CD64, CD117, HLA-DR, and cMPO.
Discussion
The FAB classification scheme (1976) divided AML into subtypes based on the morphology of BM or PB cells, while the current World Health Organization (WHO) classification system incorporates morphology, cytogenetics, molecular genetics, and immunological markers for the diagnosis of AML subtypes [2, 5, 8] . Acute myeloid leukemia is divided into two subtypes with different treatments and prognoses, AML-M2 and APL (AML-M3), depending on the magnitude of the increase in myeloblasts or abnormal promyelocytes [3] [4] [5] . Here, we provide evidence for a mixed phenotype (AML-M2/M3) with the characteristics of both AML-M2 and AML-M3. The clonal and temporal relationship between APL and the secondary AML subtype are usually obscure [20] [21] [22] [23] . In fact, a chimeric M3:M2 case of acute promyelocytic leukemia was recently presented [24] .
According to the diagnostic criteria for AML, AML-M2 is characterized by significantly increased myeloblasts, while AML-M3 is associated with abnormal promyelocytes. However, six of our cases meet the diagnostic criteria for both AML-M2 (>30% myeloblasts) and AML-M3 (>30% abnormal promyelocytes). We also observed two patients with both the AML1/ETO and the PML/RARα fusion gene. Such cases cannot be classified as AML-M2 or AML-M3, so we suggest a new subtype of AML, AML-M2/M3 [2, 5, 8, [15] [16] [17] .
The diagnosis of AML-M2/M3 requires all available information, including morphology, cytochemistry, immunophenotyping, genetics, and clinical features [2, 8] . In particular, BM cell morphology and the presence of the PML/RARа and/or AML1/ETO fusion gene define this subtype, while the immunophenotype is not sufficiently distinct from previously defined subtypes for diagnosis.
In BM and PB smears, all cases showed a simultaneous increase in myeloblasts and abnormal promyelocytes. Some promyelocytes contained dust-like or sparsely distributed granules. Promyelocyte nuclei were kidney-shape or even bi-lobed with inconspicuous to prominent nucleoli. Some promyelocytes also contained Aure rods. +, positive, showed the symptoms; -, negative, no such symptom; ±, the symptoms were not prominent. WBC, white blood cell count in peripheral blood; RBC, red blood cell count; HB, hemoglobin; LDH, lactate dehydrogenase; PT, prothrombin time; APTT, activated partial thromboplastin time; BM, bone marrow; PB, peripheral blood; MPO, myeloperoxidase; AS-DCE, naphthol AS-D chloroacetate esterase; NSE, non-specific esterase (or alpha-naphthol acetate esterase, a-NAE); -, no results available.
These morphological characteristics are distinct from the typical abnormal promyelocytic cells observed in AML-M3 [1] [2] [3] .
Immunophenotyping showed that the SSCs expressed CD9, CD11b, CD13, CD15, CD33, CD34, CD38, CD45, CD56, CD64, CD117, and HLA-DR, antigens characteristic of both AML-M2 and AML-M3. Three cases expressed BM cells strongly positive for CD9 and four cases exhibited cells strongly positive for CD13 and CD33. Two of 6 cases exhibited cells with CD117 expression. In addition, CD34, cMPO, CD117, HLA-DR, CD11b, CD15, CD38, CD56, and CD64 were expressed in some cases. However, it is difficult to distinguished AML-M2 from AML-M3 according to immunophenotype [25] [26] [27] .
It is uncertain whether the two cases with both fusion genes harbor two genetic rearrangements within the same clone or two independent clones with different rearrangements. Unfortunately, as this was a retrospective study, no further analysis was possible and there was no information on how the various FACS and molecular assays were performed. Further studies are needed to examine the frequency of this double genetic rearrangement in AML-M2/M3.
Many of the clinical characteristics of AML-M2/M3 are common to other subtypes of leukemia, including anemia, fever, hemorrhage, and infiltration. However, this group of patients was prone to DIC, cerebral hemorrhage, and other serious complications, with high mortality rates. Moreover, patients showed a trend for recurrence and transformation into AML-M2 [3, 4] . Although some clinical procedures including transplantation of stem cell has been proposed in the present investigation, the suggestion was preliminary, not original and might not be general for all similar cases. Anyhow, we analyzed the treatment effects of ATRA, ATO, or CRINT combined with the DA regimen on seven patients with AML-M2/M3, whose clinical and laboratory features were analyzed scientifically and the data revealed that there were elevated myeloblasts and abnormal promyelocytes. Because up to now, there has been no uncontested criterion for the FAB sub-classification of AML, analyzing particular cases of AML without scientific genaralization of considered particular cases still is of some significance. Thus, it remains to be investigated in FAB sub-classification of AML and its clinical treatment. In addition, further studies are needed to examine the frequency of this double genetic rearrangement in AML-M2/M3.
At present, there are no guidelines for the treatment of this new subtype of AML. All of the patients were treated with ATRA, ATO, or CRINT combined with the DA regimen and five achieved complete temporary remission. Our initial observations suggest that hematopoietic stem cell transplantation may be beneficial for long-term survival. Therefore, the significance of the present study was that the patients with AML could be treated with ATRA, ATO, or CRINT combined with the DA regimen, and hematopoietic stem cell transplantation might be beneficial for long-term survival, possibly providing data for the guidelines for the FAB sub-classification and treatment of this new subtype of AML.
In the present study, we identified a novel entity of AML according to FAB classification and examined its clinical characteristics. Although the "gray-zone" entity Table 4 Genetics features of 7 patients with AML-M2/M3 [28] , the potential fermentation concerning discrimination between M2 and M3 has been asserted. The group noted that M2 was diagnosed when mature myeloid cells were over 10%, even though "few" promyelocytes or later cells were present, indicating that M2 does not contain cases with "massive" promyelocytes. Therefore, according to the revised FAB criteria, the presented cases were not totally consistent with M2. In contrast, blasts percentage >30% did not exclude M3 diagnosis. Indeed, myeloblasts occupy >30% in about 10% of M3 cases [29] . Microscopic features of promyelocytes in the presented cases including sparse granules and bilobed nucleus were characteristics of AML M3 variant. Thus, we regarded the cases as AML-M2/M3, which remains to be further explored. Anyhow, the present investigation added new information for the analysis of AML-M2/M3. In conclusion, the clinical and laboratory features of seven patients with AML-M2/M3 are demonstrated in the present study, providing information on the FAB sub-classification. 
